Sharma Kumkum, Sharma Sumit B, Pukhta Imran A, Sharma Amit B, Salaria Abdul Q
Department of Transfusion Medicine, Acharya Shri Chander College of Medical Sciences and Hospital, Sidhra, Jammu, India.
Asian J Transfus Sci. 2013 Jan;7(1):42-7. doi: 10.4103/0973-6247.106733.
To study whether the administration of recombinant human erythropoietin increases the amount of autologous blood that can be collected before orthopaedic surgery.
We conducted a randomized controlled trial of recombinant human erythropoietin in 68 adults scheduled for elective orthopedic procedures. The patients received either erythropoietin 600 units/kg of body weight or placebo intravenously every 5(th) day prior to each phlebotomy for 21 days during which time up to 5 units of blood was collected. Patients were excluded from donation when their hematocrit values were less than 33%. All patients received iron sulphate 325mg orally 3 times daily. The mean number of units collected per patient was 4.33 ± 0.4 for erythropoietin group and 3.05± 0.71 for the placebo group.
The mean packed red cell volume donated by patients who received erythropoietin was 32% greater than that donated by patients who received placebo (196.3 vs. 169.4 ml, p<0.05). 68% in the placebo group and 9% of patients treated with erythropoietin were unable to donate ≥4 units. No adverse effects were attributed to erythropoietin. While participating in the study, complications developed in 2 patients one in each group necessitating their removal from the study.
We conclude that recombinant human erythropoietin increases the ability of the patients about to undergo elective surgery to donate autologous blood units.
研究重组人促红细胞生成素的使用是否能增加骨科手术前可采集的自体血数量。
我们对68例计划进行择期骨科手术的成年人进行了一项关于重组人促红细胞生成素的随机对照试验。在每次放血前，患者每5天静脉注射一次促红细胞生成素，剂量为600单位/千克体重，或注射安慰剂，共持续21天，在此期间最多采集5单位血液。当患者的血细胞比容值低于33%时，将被排除在献血之外。所有患者每日口服硫酸亚铁325毫克，每日3次。促红细胞生成素组每位患者采集的平均单位数为4.33±0.4，安慰剂组为3.05±0.71。
接受促红细胞生成素治疗的患者所捐献的平均红细胞压积比接受安慰剂治疗的患者高32%（196.3对169.4毫升，p<0.05）。安慰剂组68%的患者和接受促红细胞生成素治疗的患者中有9%无法捐献≥4单位血液。未发现促红细胞生成素的不良反应。在参与研究期间，两组各有1例患者出现并发症，需要退出研究。
我们得出结论，重组人促红细胞生成素可提高即将接受择期手术患者捐献自体血单位的能力。
